Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Forkhead box protein K2 (FOXK2) is a transcription factor belonging to the forkhead family, characterized by a conserved forkhead (FKH) DNA-binding domain. FOXK2 regulates gene expression by binding specific DNA motifs, recruits chromatin-modifying complexes, and acts as a scaffold for co-regulators. It controls diverse processes such as cell proliferation, cell cycle progression, DNA repair, and embryonic development. Altered FOXK2 function or expression has been implicated in various cancers, where it can act as both a tumor suppressor and promoter, depending on context. It interacts with partners including AP-1, BAP1, ERα, and DVL, influencing signaling pathways like Wnt and estrogen receptor signaling. There are currently no direct drugs available for FOXK2, but its broad involvement in oncogenesis and cell fate regulation makes it a significant molecular target of interest for future therapeutic development[1][2][3].
Not applicable (no direct drugs known). Research is ongoing for indirect or pathway-based modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Forkhead box protein K2 (FOXK2).